European Journal of Clinical Pharmacology

, Volume 11, Issue 1, pp 27–32 | Cite as

Influence of acute renal failure on the protein binding of drugs in animals and in man

  • F. M. Belpaire
  • M. G. Bogaert
  • M. M. Mussche
Originals

Summary

Serum protein binding of phenylbutazone has been measured in the rat, guinea pig, cat, rabbit and dog, and the influence on it of renal failure induced by uranyl nitrate injection has been studied. In all species a clearcut decrease in binding was observed after the occurrence of renal failure; the time course of the fall in binding correlated well with development of renal failure. In further experiments, serum protein binding of two acidic drugs (phenylbutazone, warfarin), two basic drugs (papaverine, quinidine) and one neutral drug (digitoxin) was studied in rabbits with experimental renal failure, and the results compared with those obtained in patients with acute renal failure. In the rabbits, a decrease in the binding of phenylbutazone, warfarin, papaverine and quinidine was found, whereas protein binding of digitoxin was unchanged. In man, there was a definite fall in protein binding of phenylbutazone and digitoxin, a small decrease for warfarin and papaverine, and a slight increase for quinidine.

Key words

Protein binding acute renal failure phenylbutazone warfarin papaverine quinidine digitoxin comparative study 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Black, M., Arias, I. M.: Absorption, distribution, excretion and response to the drug in the presence of chronic renal failure. In: Handb. exp. Pharmacol. Ther., Vol XXVIII/3: Concepts in Biochem. Pharmacol. (ed. J. R. Gillette and J. R. Mitchell), pp. 258–271. Berlin, Heidelberg, New York: Springer 1975Google Scholar
  2. 2.
    Prescott, L. F.: Pathological and physiological factors affecting drug absorption, distribution, elimination and response in man. In: Handb. exp. Pharmacol. Ther., Vol. XXVIII/3: Concepts in Biochem. Pharmacol. (ed. J. R. Gillette and J. R. Mitchell), pp. 234–257. Berlin, Heidelberg, New York: Springer 1975Google Scholar
  3. 3.
    Reidenberg, M. M., Affrime, M.: Influence of disease on binding of drugs to plasma proteins. Ann. N. Y. Acad. Sci.226, 115–126 (1973)Google Scholar
  4. 4.
    Skuterud, B., Enger, E., Halvorsen, S., Jacobsen, S., Lunde, P. M. K.: Serum protein binding of quinidine and diphenylhydantoin in healthy human volunteers and in patients with chronic renal failure. In: The basis of drug therapy in man. Fifth Internat. Congr. Pharmacolog. pp. 79–80. San-Francisco: 1972Google Scholar
  5. 5.
    Baker, R.: Serum albumin in uremia: A clinical investigation correlated with reversible uremia in dogs. J. Urol. (Baltimore)65, 197–211 (1951)Google Scholar
  6. 6.
    Taylor, J. D., Richards, R. K., Davin, C. J., Asher, J.: Plasma binding of thiopental in the nephrectomized rabbit. J. Pharmacol. exp. Ther.112, 40–48 (1954)Google Scholar
  7. 7.
    Nilsen, O. G., Fremstad, D., Jacobsen, S.: Increased binding of quinidine to serum albumin and lipoproteins in anuric rats. Europ. J. Pharmacol.33, 131–139 (1975)Google Scholar
  8. 8.
    Flamenbaum, W., Huddleston, M. L., McNeil, J. S., Hamburger, R. J.: Uranyl nitrate-induced acute renal failure in the rat: Micropuncture and renal hemodynamic studies. Kidney Int.6, 408–418 (1974)Google Scholar
  9. 9.
    Dromgoole, S. H.: The binding capacity of albumin and renal disease. J. Pharmacol. exp. Ther.191, 318–323 (1974)Google Scholar
  10. 10.
    Scatchard, G.: The attraction of proteins for small molecules and ions. Ann. N. Y. Acad. Sci.51, 660–672 (1949)Google Scholar
  11. 11.
    Belpaire, F. M., Bogaert, M. G.: The excretion of3H-papaverine in the rat. Biochem. Pharmacol.22, 59–66 (1973)Google Scholar
  12. 12.
    Cramer, G., Isaksson, B.: Quantitative determination of quinidine in plasma. Scand. J. clin. Lab. Invest.15, 553–556 (1963)Google Scholar
  13. 13.
    Andreasen, F.: Protein binding of drugs in plasma from patients with acute renal failure. Acta pharmacol. (Kb h.)32, 417–429 (1973)Google Scholar
  14. 14.
    Mussche, M. M., Belpaire, F. M., Bogaert, M. G.: Plasma protein binding of phenylbutazone during recovery from acute renal failure. Europ. J. clin. Pharmacol.9, 69–71 (1975)Google Scholar
  15. 15.
    Olsen, G. D., Bennett, W. M., Porter, G. A.: Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin. Pharmacol. Ther.17, 677–684 (1975)Google Scholar
  16. 16.
    Belpaire, F. M., Bogaert, M. G., De Broe, M., Mussche, M. M.: Serum binding of quinidine in experimental acute renal failure. Pharmacology (Basel) in pressGoogle Scholar
  17. 17.
    Shoeman, D. W., Azarnoff, D. L.: The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology (Basel)7, 169–177 (1972)Google Scholar
  18. 18.
    Rasmussen, J., Jervell, J., Storstein, L., Gjerdrum, K.: Digitoxin kinetics in patients with impaired renal function. Clin. Pharmacol. Ther.13, 6–14 (1972)Google Scholar
  19. 19.
    O'Malley, K., Velasco, M., Pruitt, A., McNay, J. L.: Decreased plasma protein binding of diazoxide in uremia. Clin. Pharmacol. Ther.18, 53–58 (1975)Google Scholar
  20. 20.
    Gugler, R., Shoeman, D. W., Huffman, D. H., Cohlmia, J. B., Azarnoff, D. L.: Pharmacokinetics of drugs in patients with the nephrotic syndrome. J. clin. Invest.55, 1182–1189 (1975)Google Scholar

Copyright information

© Springer-Verlag 1977

Authors and Affiliations

  • F. M. Belpaire
    • 1
  • M. G. Bogaert
    • 1
  • M. M. Mussche
    • 1
  1. 1.Heymans Institute of Pharmacology and Department of NephrologyUniversity of Ghent, Medical SchoolGhentBelgium

Personalised recommendations